Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b

27 Aug 2009

Abstract excerpt

BACKGROUND: The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. DESIGN AND METHODS: In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed gene expression profiling of the KMS18 multiple myeloma cell line treated with the drug. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19713220
DOI: 10.3324/haematol.2009.012088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bPMID 19713220Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor PicropodophyllinSemantic proximity Read ↗

Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq DataSemantic proximity Read ↗

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplificationSemantic proximity Read ↗

Master and servant: LINC00152 – a STAT3-induced long noncoding RNA regulates STAT3 in a positive feedback in human multiple myelomaSemantic proximity Read ↗

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and AiolosSemantic proximity Read ↗

The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myelomaSemantic proximity Read ↗

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cellsSemantic proximity Read ↗

Epigenetic Silencing of the Human Nucleotide Excision Repair Gene, hHR23B, in Interleukin-6-responsive Multiple Myeloma KAS-6/1 CellsSemantic proximity Read ↗

Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.Semantic proximity Read ↗

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple MyelomaSemantic proximity Read ↗

miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.